Menopur

INSTRUCTION for medical use of the medicinal product MENOPUR (MENOPUR®)

Composition

Menopur 600 IU:

• Active substance: highly purified menotropin;
• 1 vial with powder contains highly purified menotropin (highly purified human menopausal gonadotropin, hMG) equivalent to 600 IU FSH (follicle-stimulating hormone) and 600 IU LH (luteinizing hormone).

Menopur 1200 IU:

• Active substance: highly purified menotropin;
• 1 vial with powder contains highly purified menotropin (highly purified human menopausal gonadotropin, hMG) equivalent to 1200 IU FSH (follicle-stimulating hormone) and 1200 IU LH (luteinizing hormone);
• Excipients: lactose monohydrate; sodium hydrogen phosphate heptahydrate; polysorbate 20; 1 M phosphoric acid solution; 0.5 M sodium hydrogen phosphate heptahydrate solution;
• 1 syringe with solvent contains: m-cresol, water for injections.

Pharmaceutical form

Lyophilized powder for solution for injection.

Basic physicochemical properties

• Powder: white or almost white lyophilisate in the form of a cake;
• Solvent: clear, colorless solution.

Pharmacotherapeutic group

Gonadotropins and other ovulation stimulants. Human menopausal gonadotropin. ATC code: G03GA02.

Pharmacological properties

Pharmacodynamics

Menopur contains human chorionic gonadotropin (hCG) – a natural hormone found in the urine of postmenopausal women, which primarily provides LH activity. Menotropin, possessing both FSH and LH activity, induces follicular growth and development, as well as gonadal steroid secretion in women who do not suffer from primary ovarian insufficiency. FSH initially initiates the resumption of follicular growth at the early folliculogenesis stage, while LH is important for ovarian steroidogenesis and participates in physiological processes leading to the development of a suitable preovulatory follicle.

Follicular growth can be stimulated by FSH even in the complete absence of LH, but the resulting follicles develop abnormally. Additionally, such stimulation is associated with low estradiol levels, leading to inadequate luteinization. In line with the LH-driven enhancement of steroidogenesis, in IVF/ICSI cycles with pituitary desensitization, estradiol levels during Menopur treatment are higher than with recombinant FSH preparations. This should be considered when monitoring patient response via estradiol level measurements. No differences in achieved estradiol levels were observed when using low-dose ovulation induction protocols in anovulatory patients.

Pharmacokinetics

The pharmacokinetic profile of FSH in Menopur has been studied. After 7 days of administration of 150 IU Menopur to healthy female volunteers with desensitized pituitary glands, maximum plasma concentrations of FSH (baseline-corrected) (mean ± SD) were 8.9 ± 3.5 IU/L and 8.9 ± 3.5 IU/L following subcutaneous and intramuscular administration, respectively. Maximum FSH concentrations are reached within 7 hours after administration by both routes. After repeated dosing, the elimination half-life of FSH is 30 ± 11 hours and 27 ± 9 hours following subcutaneous and intramuscular administration, respectively (mean ± SD).

Although individual LH concentrations increase over time after Menopur administration, available data are insufficient for pharmacokinetic analysis. Menotropin is primarily eliminated by the kidneys. Pharmacokinetics of Menopur in patients with impaired renal or hepatic function have not been studied.

Clinical characteristics

Indications

Treatment of infertility in the following clinical conditions:

• Anovulation, including polycystic ovary syndrome (PCOS), in women who have shown no response to clomiphene citrate treatment;
• Controlled ovarian hyperstimulation to induce development of multiple follicles as part of assisted reproductive technologies (ART) (e.g., in vitro fertilization/embryo transfer (IVF/ET), gamete intrafallopian transfer (GIFT), and intracytoplasmic sperm injection (ICSI));
• Stimulation of follicular growth in women with hypogonadotropic hypogonadism.

Contraindications

Menopur is contraindicated in women:

• With hypersensitivity to the active substance or any of the excipients;
• With pituitary or hypothalamic tumors;
• With ovarian, uterine, or breast carcinoma;
• With gynecological bleeding of unknown etiology;
• With premature menopause;
• With ovarian cysts or enlarged ovaries not related to polycystic ovary syndrome (PCOS);
• During pregnancy or breastfeeding.

Menopur should not be prescribed when a favorable treatment outcome is unlikely:

• In primary ovarian insufficiency;
• In congenital malformations of genital organs incompatible with pregnancy;
• In uterine fibroids incompatible with pregnancy.

Interaction with other medicinal products and other forms of interaction

Drug interactions of Menopur in humans have not been studied. Even in the absence of clinical experience, concomitant use of Menopur and clomiphene citrate is expected to enhance follicular response. When using GnRH agonists for pituitary desensitization, higher doses of Menopur may be required to achieve adequate follicular response.

Special precautions for use

Since Menopur has strong gonadotropic activity that may cause mild to moderate adverse effects, it should be administered under the supervision of physicians specialized in infertility treatment and experienced in such therapy. Gonadotropin treatment requires careful medical supervision and regular monitoring of ovarian response, including ultrasound examinations, possibly combined with serum estradiol level measurements.

Ovarian response to menotropin administration varies significantly among patients, with some showing poor response. The lowest effective dose corresponding to the treatment goal should be used. The first Menopur injection should be administered under direct physician supervision.

Before initiating treatment, infertility diagnosis should be confirmed in the couple, and contraindications to pregnancy should be ruled out. In particular, patients should be evaluated for hypothyroidism, adrenal insufficiency, hyperprolactinemia, and pituitary or hypothalamic tumors, and appropriate treatment initiated if necessary.

In patients undergoing follicular growth stimulation for anovulatory infertility or ART procedures, ovarian enlargement or hyperstimulation may occur. These risks can be minimized by strictly adhering to recommended dosing and administration regimens and careful therapy monitoring. Accurate assessment of follicular development and maturation should be performed by a physician experienced in interpreting relevant tests.

Ovarian Hyperstimulation Syndrome (OHSS)

OHSS is a distinct clinical condition different from uncomplicated ovarian enlargement. OHSS is a syndrome with increasing severity. Signs of OHSS include ovarian enlargement, high serum sex hormone levels, and increased vascular permeability, potentially leading to fluid accumulation in the peritoneal, pleural, and in rare cases, pericardial cavities.

Severe OHSS may present with abdominal pain, abdominal distension, marked ovarian enlargement, weight gain, dyspnea, oliguria, and gastrointestinal symptoms such as nausea, vomiting, and diarrhea. Clinical examination may reveal hypovolemia, hemoconcentration, electrolyte imbalance, ascites, hemoperitoneum, pleural effusion, hydrothorax, acute respiratory insufficiency, and thromboembolism.

Excessive ovarian response to gonadotropin treatment rarely leads to OHSS until hCG is administered to trigger ovulation. Therefore, in cases of ovarian hyperstimulation, hCG should not be administered; patients should be advised to abstain from sexual intercourse or use barrier contraception for at least 4 days.

OHSS can progress rapidly (within 24 hours to several days) and become severe; therefore, patients should remain under medical supervision for at least 2 weeks after hCG administration. The risk of ovarian hyperstimulation and multiple pregnancy can be minimized by following recommended dosing and administration regimens and careful treatment monitoring. In ART procedures, the risk of hyperstimulation can be reduced by aspirating all follicles before ovulation.

OHSS may become more severe and prolonged if pregnancy occurs. OHSS most commonly develops after completion of hormonal therapy, reaching peak incidence approximately 7–10 days after treatment ends. Typically, OHSS resolves spontaneously with the onset of menstruation. In cases of severe OHSS, gonadotropin treatment should be discontinued. If OHSS persists, hospitalization and specific OHSS treatment are required. This syndrome is more frequently observed in women with polycystic ovary syndrome (PCOS).

Multiple pregnancies

Multiple pregnancies, especially higher-order multiples, increase the risk of complications for both mother and child. In patients undergoing ovulation induction with gonadotropins, the frequency of multiple pregnancies is higher than with natural conception. Most multiple pregnancies are twins. To reduce the risk of multiple pregnancy, careful monitoring of ovarian response is recommended. In patients undergoing ART procedures, the risk of multiple pregnancies primarily depends on the number of embryos transferred, embryo quality, and patient age. Patients should be informed about the potential risk of multiple pregnancy before treatment initiation.

Pregnancy loss

The frequency of pregnancy loss – preterm delivery and spontaneous abortion – is higher in patients undergoing follicular stimulation as part of ART procedures compared to the general patient population.

Ectopic pregnancy

Women with a history of tubal disease have an increased risk of ectopic pregnancy, regardless of whether pregnancy occurs spontaneously or following infertility treatment. After IVF, the reported incidence of ectopic pregnancy is 2–5%, compared to 1–1.5% in the general population.

Reproductive system neoplasms

Cases of benign and malignant neoplasms of the ovaries and other reproductive organs have been reported in women treated with multiple infertility drugs. It has not yet been established whether gonadotropin treatment increases the baseline risk of such tumors in infertile women.

Congenital malformations

The prevalence of congenital malformations after ART may be slightly higher than after spontaneous conception. This is believed to result from differences in parental characteristics (e.g., maternal age, sperm characteristics) and multiple pregnancies.

Thromboembolic complications

Women with recognized risk factors for thromboembolic complications, such as a history of thromboembolic disease, familial cases of such disease, severe obesity (BMI > 30 kg/m²), or thrombophilia, have an increased risk of venous or arterial thromboembolism during or after gonadotropin treatment. In such women, the benefits of gonadotropin use should be weighed against potential risks. However, it should be noted that pregnancy itself is also a risk factor for thromboembolic complications.

Important information about excipients

This medicinal product contains less than 1 mmol (23 mg)/dose of sodium, i.e., essentially sodium-free.

Use during pregnancy or breastfeeding

Menopur is contraindicated in pregnant women. Data on the use of menotropin in pregnant women are lacking or limited. Animal studies on the effects of Menopur during pregnancy have not been conducted. Menopur is contraindicated in women who are breastfeeding.

Ability to affect reaction speed when driving or operating machinery

Appropriate studies have not been conducted. However, it is unlikely that Menopur affects the ability of patients to drive or perform work requiring high attention and rapid reaction.

Method of administration and dosage

Treatment with Menopur should be initiated under the supervision of a physician experienced in infertility treatment. Menopur 600 IU and Menopur 1200 IU are intended for subcutaneous administration after reconstitution with solvent, as the syringe provided in the package is designed only for subcutaneous injection. The powder must be dissolved before use. The prepared solution is intended for multiple uses and can be stored for up to 28 days. Avoid vigorous shaking during reconstitution. The solution should not be used if it is cloudy or contains particles.

The dosing regimens described below are applicable for both subcutaneous and intramuscular administration. Ovarian response to exogenous gonadotropins is individual, making it impossible to establish a single universal dosing regimen. Therefore, dosing should be individualized according to ovarian response. Menopur can be used as monotherapy or in combination with a gonadotropin-releasing hormone (GnRH) agonist or antagonist. Recommended doses and treatment duration depend on the treatment protocol used.

Women with anovulation (including PCOS)

The goal of Menopur therapy is the development of a single Graafian follicle, from which an oocyte is released after administration of human chorionic gonadotropin (hCG). Menopur therapy should be initiated within the first 7 days of the menstrual cycle. The recommended daily starting dose of Menopur is 75–150 IU, which should be maintained for at least 7 days. The subsequent treatment regimen should be individualized according to ovarian response and clinical monitoring results (including ultrasound examinations, possibly combined with estradiol level measurements). The dose should not be changed more frequently than every 7 days. The recommended dose increment is 37.5 IU, not exceeding 75 IU. The maximum daily dose should not exceed 225 IU.

If an inadequate response is observed after 4 weeks of treatment, the therapeutic cycle should be discontinued, and a new cycle initiated with a higher dose than used in the previous cycle. Upon achieving optimal response, a single dose of hCG (5000–10000 IU) should be administered one day after the last Menopur injection. Patients are advised to have sexual intercourse on the day of hCG administration and the following day. Alternatively, intrauterine insemination (IUI) may be performed.

If an excessive response to Menopur is observed, treatment should be discontinued and hCG administration canceled (see section "Special precautions for use"). The patient should use a barrier contraceptive method or abstain from sexual intercourse until the onset of the next menstrual bleeding.

Women undergoing controlled ovarian hyperstimulation for induction of multiple follicular development as part of assisted reproductive technologies (ART)

Based on clinical trial results using Menopur with pituitary desensitization using a GnRH agonist, Menopur therapy should be initiated approximately 2 weeks after starting the agonist. During at least the first 5 days of treatment, Menopur should be administered at a daily dose of 150–225 IU. Subsequent dosing should be individualized according to patient response and clinical monitoring (including ultrasound examinations, possibly combined with estradiol level measurements), with dose increments not exceeding 150 IU. The maximum daily dose should not exceed 450 IU. In most cases, treatment should not be continued for more than 20 days.

For protocols not involving desensitization with GnRH agonists, Menopur therapy should be initiated on day 2 or 3 of the menstrual cycle. The same dosing and administration regimen as for protocols with GnRH agonist desensitization is recommended.

When a sufficient number of follicles of appropriate size are formed, a single dose of hCG (up to 10000 IU) should be administered to induce final follicular maturation. The patient should remain under careful medical observation for at least 2 weeks after hCG administration.

If an excessive response to Menopur is observed, treatment should be discontinued and hCG administration canceled (see section "Special precautions for use"). The patient should use a barrier contraceptive method or abstain from sexual intercourse until the onset of the next menstrual bleeding.

Preparation of Menopur 600 IU and 1200 IU solution

If your clinic has instructed you to self-administer Menopur injections, you should follow all provided instructions. Menopur is intended for subcutaneous administration, preferably in the abdominal area. The first Menopur injection should be administered under the supervision of a physician or nurse. Patients must be well-informed about the method of Menopur administration. Only well-motivated and trained patients may self-administer the drug, and they should be able to consult with their physician.

Menopur 600 IU: Menopur is supplied as a powder in a vial and must be reconstituted before injection using one syringe filled with solvent. The solvent to be used for reconstituting Menopur is contained in a pre-filled syringe in the package. Menopur 600 IU should be reconstituted using one pre-filled syringe with solvent. After reconstitution, the vial contains sufficient medication for several days of therapy; therefore, ensure that you draw up no more than the dose prescribed by your physician.

Your physician has prescribed a Menopur dose in IU (units). To obtain the required dose, use one of the 9 provided injection syringes, graduated in IU (units) of FSH/LH.

This should be done as follows:

1. Remove the protective cap from the vial containing the powder and the rubber cap from the pre-filled solvent syringe (Figure 1).

2. Firmly attach the needle (reconstitution needle) to the pre-filled solvent syringe and remove the protective cap from the needle (Figure 2).

3. Insert the needle vertically through the center of the rubber stopper on the vial containing the powder and slowly inject the entire amount of solvent, avoiding the formation of bubbles (Figure 3).

4. After adding the solvent, a slight overpressure may develop inside the vial. Therefore, release the syringe plunger and allow it to rise on its own for approximately 10 seconds. This will help relieve the overpressure in the vial (Figure 4).

Remove the syringe and reconstitution needle.

1. The powder should dissolve quickly (within 2 minutes), forming a clear solution. Although this usually occurs when only a few drops of solvent are added, the solvent should be added in the full volume. To facilitate dissolution of the powder, the solution should be mixed by gently swirling the vial (Figure 5). Do not shake, as this may cause formation of air bubbles.

The vial containing the powder reconstituted using one pre-filled syringe with solvent is ready for use. If the solution is not clear or contains particles, it should not be used.

1. Take the injection syringe with the pre-attached needle and insert the needle vertically into the center of the vial. The injection syringe already contains a small amount of air, which should be injected into the vial above the liquid. Invert the vial upside down and draw the prescribed dose of Menopur into the injection syringe (Figure 6).

REMEMBER: since this vial contains medication sufficient for several days of therapy, you must ensure that you draw up no more than the dose prescribed by your doctor. If Bravelle has been prescribed together with Menopur, you may mix these two medicinal products by reconstituting Menopur and injecting the prescribed dose of Menopur into the reconstituted Bravelle solution. Draw up the mixed solution: you may then administer both medicinal products together, instead of injecting each separately.

1. Remove the syringe from the vial and draw a small amount of air into the syringe (Figure 7).
2. Gently tap the injection syringe so that all air bubbles collect in the hub (Figure 8). Carefully expel all air and continue pressing until the first drop of liquid appears at the needle tip.

Your doctor or nurse will instruct you where to administer the injection (e.g., the front of the thigh, abdomen, etc.). Before administering the injection, disinfect the injection site using the alcohol swabs provided in the package.

1. To administer the injection, pinch the skin to form a skin fold and insert the needle in one quick motion at a 90-degree angle to the body. Gently push the plunger to inject the solution (Figure 9), then remove the syringe.

After removing the syringe, apply pressure to the injection site to stop bleeding. Gently massaging the injection site will help spread the solution under the skin. Do not dispose of used materials in household waste; they must be properly discarded.

1. To administer the next injection of the reconstituted Menopur solution, repeat steps 6–9.

Menopur 1200 IU

Menopur is supplied as a powder in a vial and must be reconstituted prior to injection using two pre-filled syringes containing solvent. The solvents to be used for reconstituting Menopur are provided in pre-filled syringes within the package. Menopur 1200 IU must be reconstituted before use with two pre-filled syringes containing solvent. After reconstituting the powder with the solvent, this vial contains a sufficient amount of medicinal product for several days of therapy; therefore, you must ensure that you draw up no more than the dose prescribed by your doctor. Your doctor has prescribed your Menopur dose in IU (international units). To obtain the required dose, you must use one of the 18 provided administration syringes, graduated in IU of FSH/LH.

This should be done as follows:

1. Remove the protective cap from the vial containing the powder and the rubber cap from one of the pre-filled syringes containing the solvent (Figure 1).
   
2. Firmly attach the needle (reconstitution needle) to the pre-filled syringe containing the solvent and remove the protective cap from the needle (Figure 2).

1. Insert the needle vertically through the center of the rubber stopper on the vial containing the powder and slowly inject all of the diluent, avoiding the formation of bubbles (Figure 3).
2. After adding the diluent, a slight overpressure may develop in the vial. Therefore, release the syringe plunger to allow it to rise automatically for approximately 10 seconds. This will help eliminate excess pressure in the vial (Figure 4).
3. Carefully disconnect the syringe from the needle by twisting it, leaving the needle in the vial.

Remove the protective cap from the second prefilled syringe containing the diluent and firmly attach the syringe to the needle secured in the vial. Slowly inject all the diluent, avoiding the formation of bubbles (Figure 5).

1. After adding the diluent, a slight overpressure may develop in the vial. Therefore, release the syringe plunger to allow it to rise automatically for approximately 10 seconds. This will help eliminate excess pressure in the vial (Figure 6).

Remove the reconstitution syringe and needle.

1. The powder should dissolve quickly (within 2 minutes), forming a clear solution. Although this usually occurs upon addition of just a few drops of solvent, the solvent should be added in full volume. To facilitate dissolution of the powder, gently swirl the vial (Figure 7). Do not shake, as this may cause formation of air bubbles.

The vial containing the reconstituted powder using two pre-filled syringes with solvent is ready for use. If the solution is not clear or contains particles, it must not be used.

1. Take the injection syringe with the pre-attached needle and insert the needle vertically into the center of the vial stopper. The injection syringe already contains a small amount of air, which should be injected into the vial above the liquid. Invert the vial and draw the prescribed dose of Menopur into the injection syringe (Figure 8).

REMEMBER: Since this vial contains medication sufficient for several days of treatment, you must ensure that you draw up no more than the dose prescribed by your doctor. If Bravelle has been prescribed together with Menopur, you may mix these two medications by reconstituting Menopur and injecting the prescribed dose of Menopur into the reconstituted Bravelle solution. Draw up the mixed solution: you may then administer both medications together, instead of injecting each separately.

1. Remove the syringe from the vial and draw a small amount of air into the syringe (Figure 9).
2. Gently tap the injection syringe to allow all air bubbles to rise to the hub. Carefully expel all air, continuing to press until the first drop of liquid appears at the needle tip.

Your doctor or nurse will instruct you where to administer the injection (e.g., front of the thigh, abdomen, etc.). Before injecting, disinfect the injection site using the alcohol wipes provided in the pack.

1. To administer the injection, pinch the skin to create a skin fold and insert the needle quickly at a 90-degree angle to the body. Carefully press the plunger to inject the solution (Figure 11), then remove the syringe.

After removing the injection syringe, apply pressure to the injection site to stop bleeding. Gently massaging the injection site may help the solution spread under the skin. Do not dispose of used materials in regular household waste; they must be properly discarded.

1. To administer the next injection of the reconstituted Menopur solution, repeat steps 8–11.

If you have administered more Menopur than prescribed, please inform your nurse or doctor. If you forget to inject Menopur, do not inject a double dose to make up for the missed dose. Please inform your nurse or doctor.

General instructions
Do not administer the prepared solution if it contains particles or appears cloudy. Any unused medicine or waste should be disposed of according to local regulations.

Children
This medicine is not intended for use in children.

Overdose
Treatment with LH may lead to ovarian hyperstimulation, which becomes clinically apparent only after administration of hCG to induce ovulation (see section "Side effects").
Mild hyperstimulation (Grade I) is characterized by moderate ovarian enlargement (ovary size 5–7 cm), excessive steroid secretion, and abdominal pain. No treatment is required, but patients should be informed about symptoms of hyperstimulation and carefully monitored.
Moderate hyperstimulation (Grade II) with ovarian cysts (ovary size 8–10 cm) presents with abdominal pain, nausea, and vomiting. Symptomatic treatment and possibly intravenous fluid replacement may be required.
Severe hyperstimulation (Grade III) with large ovarian cysts (ovary size >10 cm), accompanied by ascites, hydrothorax, abdominal distension, abdominal pain, dyspnea, salt retention, increased hemoglobin concentration, increased blood viscosity, and platelet aggregation with risk of thromboembolism, requires hospitalization.

Side effects
The most frequently reported side effects with Menopur in clinical trials were OHSS, abdominal pain, headache, and injection site reactions and pain, each occurring at a frequency of up to 5%.
The main side effects observed in women treated with Menopur in clinical trials are listed below, categorized by frequency: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000), and not known.

Eye disorders:
Frequency not known – visual disturbances^a

Gastrointestinal disorders:
Common – abdominal pain, bloating, nausea
Uncommon – vomiting, abdominal discomfort, diarrhea

General disorders and administration site conditions:
Common – injection site reactions^b
Uncommon – weakness
Frequency not known – pyrexia, malaise

Immune system disorders:
Frequency not known – hypersensitivity reactions^c

Investigations:
Frequency not known – weight gain

Musculoskeletal and connective tissue disorders:
Frequency not known – musculoskeletal pain^d

Nervous system disorders:
Common – headache
Uncommon – dizziness

Reproductive system and breast disorders:
Common – OHSS^e, pelvic pain^f
Uncommon – ovarian cyst, breast discomfort^g
Frequency not known – ovarian torsion^e

Skin and subcutaneous tissue disorders:
Rare – acne, rash
Frequency not known – pruritus, urticaria

Cardiovascular disorders:
Uncommon – hot flushes
Frequency not known – thromboembolism^e

^a Isolated cases of transient amaurosis, diplopia, mydriasis, scotoma, photopsia, floaters, blurred vision, and visual disorders have been reported as visual disturbances during the post-marketing period.
^b Injection site reactions were most commonly reported as injection site pain.
^c There have been reports of rare cases of localized or generalized allergic reactions, including anaphylactic reactions, accompanied by corresponding symptoms.
^d Musculoskeletal pain includes arthralgia, back pain, neck pain, and limb pain.
^e In clinical trials with Menopur, gastrointestinal symptoms associated with OHSS such as bloating, discomfort, nausea, vomiting, and diarrhea were reported. Cases of severe OHSS-related ascites, pelvic fluid accumulation, pleuritis, dyspnea, oliguria, thromboembolic events, and ovarian torsion were reported as rare complications.
^f Pelvic symptoms include ovarian pain and uterine prolapse.
^g Breast-related complaints include breast pain, breast tenderness, discomfort, nipple pain, and breast swelling.

Shelf life
3 years. After reconstitution, the solution may be stored for up to 28 days at a temperature not exceeding 25°C.

Storage conditions
Keep out of the reach of children. Store in the refrigerator (2–8°C) in the original packaging. Do not freeze.

Incompatibilities
The reconstituted Menopur solution should not be mixed with other medicinal products except for the urofollitropin preparation Bravelle (FSH) manufactured by Ferring. Studies have demonstrated that co-administration of Bravelle and Menopur does not significantly affect the expected bioavailability of either product.

Packaging
Menopur 600 IU: 1 vial of powder with 1 pre-filled syringe containing 1 mL solvent, 1 reconstitution needle, and 9 injection syringes.
Menopur 1200 IU: 1 vial of powder with 2 pre-filled syringes containing 1 mL solvent each, 1 reconstitution needle, and 18 injection syringes.

Prescription category
Prescription only.

Manufacturer
Ferring GmbH, Germany

Manufacturer's address
Wittland 11, 24109 Kiel, Germany